Inozyme Pharma
We are a pioneering, clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for rare diseases that affect bone health and blood vessel function. Our lead candidate, INZ-701, is an ENPP1 Fc fusion protein enzyme replacement therapy (ERT) designed to increase PPi and adenosine, enabling the potential treatment of multiple diseases caused by deficiencies in these metabolites. By targeting the PPi-Adenosine Pathway, INZ-701 aims to correct pathological mineralization and intimal proliferation, addressing the significant morbidity and mortality in these devastating diseases. It is currently in clinical development for the treatment of ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis.
321 Summer St Suite #400
Boston, MA 02210
Boston, MA 02210
-
“At Inozyme, keeping the patient and family at the center of our work is the foundation of everything we do. Including the patient voice in our research leads to stronger clinical trials, and ultimately, potential therapeutic options that can improve the lives of patients living with rare disorders.”
Catherine Nester
SVP HCP and Patient Engagement
NEWS
Why I advocated on Capitol Hill this month for the renewal of the FDA’s Priority Review Voucher program
Money on the Move: A weekly roundup of notable funding news across biopharma industry. See who raked in funds for which diseases
Prometheus completed its Phase II trial in UC, Algernon announced its Phase II trial of IPF and chronic coffee, Seelos dosed the first patient of SLS-005 for patients with ALS.
Third Harmonic Bio, Akili Interactive, the Rare Disease Company Coalition, Inozyme, Athira, Cytovia and many more made major leadership decisions this week.
It was a very busy week for clinical trial news, with much of it coming out of the American Association of Cancer Research Annual Meeting. Read on for details.
It was a very busy week for clinical trial news, in part because of presentations coming out of the American Academy of Neurology (AAN) meeting. Here’s a look.
Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers
The grant is the latest in a steady stream of company advances highlighted by the addition of a chief financial officer in January and several collaborative agreements in the past year.
With the last full week before the Thanksgiving week in the U.S., companies had a fair amount of clinical trial news. Here’s a look.
JOBS
IN THE PRESS